Zacks Investment Research lowered shares of Autolus Therapeutics (NASDAQ:AUTL) from a hold rating to a sell rating in a research note published on Friday morning.
According to Zacks, “Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company’s pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London, United Kingdom. “
Other equities analysts have also issued research reports about the stock. Wells Fargo & Co reaffirmed a buy rating and set a $50.00 price objective (up previously from $38.00) on shares of Autolus Therapeutics in a research report on Thursday, November 29th. HC Wainwright assumed coverage on shares of Autolus Therapeutics in a research report on Wednesday, October 24th. They set a buy rating on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. Autolus Therapeutics presently has a consensus rating of Buy and an average target price of $44.00.
Shares of AUTL opened at $37.00 on Friday. Autolus Therapeutics has a twelve month low of $19.17 and a twelve month high of $53.24.
Several large investors have recently added to or reduced their stakes in the company. Capital International Investors bought a new position in shares of Autolus Therapeutics in the third quarter valued at approximately $14,745,000. Sphera Funds Management LTD. increased its position in Autolus Therapeutics by 68.3% during the third quarter. Sphera Funds Management LTD. now owns 296,251 shares of the company’s stock worth $8,935,000 after acquiring an additional 120,206 shares during the period. Partner Fund Management L.P. increased its position in Autolus Therapeutics by 11.0% during the third quarter. Partner Fund Management L.P. now owns 219,628 shares of the company’s stock worth $6,736,000 after acquiring an additional 21,754 shares during the period. Allianz Asset Management GmbH bought a new position in Autolus Therapeutics during the third quarter worth $2,033,000. Finally, Blair William & Co. IL increased its position in Autolus Therapeutics by 250.0% during the third quarter. Blair William & Co. IL now owns 30,800 shares of the company’s stock worth $945,000 after acquiring an additional 22,000 shares during the period. 44.20% of the stock is currently owned by institutional investors.
About Autolus Therapeutics
Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.
Read More: How is inflation measured?
Get a free copy of the Zacks research report on Autolus Therapeutics (AUTL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.